Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Goodwill (2023 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Goodwill for 3 consecutive years, with $48.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Goodwill changed 0.0% to $48.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $48.2 million, a 0.0% change, with the full-year FY2025 number at $48.2 million, changed 0.0% from a year prior.
  • Goodwill was $48.2 million for Q4 2025 at Cartesian Therapeutics, roughly flat from $48.2 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $48.2 million in Q4 2023 to a low of $48.2 million in Q4 2023.
  • A 3-year average of $48.2 million and a median of $48.2 million in 2023 define the central range for Goodwill.
  • Biggest YoY gain for Goodwill was 0.0% in 2024; the steepest drop was 0.0% in 2024.
  • Cartesian Therapeutics' Goodwill stood at $48.2 million in 2023, then changed by 0.0% to $48.2 million in 2024, then changed by 0.0% to $48.2 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Goodwill are $48.2 million (Q4 2025), $48.2 million (Q3 2025), and $48.2 million (Q1 2025).